JP7445826B2 - 固形腫瘍治療用医薬組成物 - Google Patents

固形腫瘍治療用医薬組成物 Download PDF

Info

Publication number
JP7445826B2
JP7445826B2 JP2023546948A JP2023546948A JP7445826B2 JP 7445826 B2 JP7445826 B2 JP 7445826B2 JP 2023546948 A JP2023546948 A JP 2023546948A JP 2023546948 A JP2023546948 A JP 2023546948A JP 7445826 B2 JP7445826 B2 JP 7445826B2
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
administered
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023546948A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023038030A5 (https=
JPWO2023038030A1 (https=
Inventor
俊行 玉井
聰 永尾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JPWO2023038030A1 publication Critical patent/JPWO2023038030A1/ja
Publication of JPWO2023038030A5 publication Critical patent/JPWO2023038030A5/ja
Application granted granted Critical
Publication of JP7445826B2 publication Critical patent/JP7445826B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023546948A 2021-09-08 2022-09-06 固形腫瘍治療用医薬組成物 Active JP7445826B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021146389 2021-09-08
JP2021146389 2021-09-08
PCT/JP2022/033458 WO2023038030A1 (ja) 2021-09-08 2022-09-06 固形腫瘍治療用医薬組成物

Publications (3)

Publication Number Publication Date
JPWO2023038030A1 JPWO2023038030A1 (https=) 2023-03-16
JPWO2023038030A5 JPWO2023038030A5 (https=) 2023-11-27
JP7445826B2 true JP7445826B2 (ja) 2024-03-07

Family

ID=85507597

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023546948A Active JP7445826B2 (ja) 2021-09-08 2022-09-06 固形腫瘍治療用医薬組成物

Country Status (9)

Country Link
US (1) US20250222003A1 (https=)
EP (1) EP4364742A4 (https=)
JP (1) JP7445826B2 (https=)
KR (1) KR20240056487A (https=)
CN (1) CN117794544A (https=)
AU (1) AU2022342537A1 (https=)
CA (1) CA3227813A1 (https=)
MX (1) MX2024002060A (https=)
WO (1) WO2023038030A1 (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110288115A1 (en) 2010-05-24 2011-11-24 Avmedis Llc Treatment of vagally-mediated spectrum disorders
WO2015098853A1 (ja) 2013-12-25 2015-07-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 （６Ｓ，９ａＳ）－Ｎ－ベンジル－６－［（４－ヒドロキシフェニル）メチル］－４，７－ジオキソ－８－（｛６－［３－（ピペラジン－１－イル）アゼチジン－１－イル］ピリジン－２－イル｝メチル）－２－（プロプ－２－エン－１－イル）－オクタヒドロ－１Ｈ－ピラジノ［２，１－ｃ］［１，２，４］トリアジン－１－カルボキサミド化合物
WO2018147275A1 (ja) 2017-02-08 2018-08-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
WO2021086909A1 (en) 2019-10-29 2021-05-06 Eisai R&D Managment Co., Ltd. Combination of a pd-1 antagonist, a vegfr/fgfr/ret tyrosine kinase inhibitor and a cbp/beta-catenin inhibitor for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160061911A (ko) * 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
CN112472699A (zh) * 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
CA2986999C (en) 2015-06-23 2023-08-08 Eisai R&D Management Co., Ltd. Crystal of (6s,9as)-n-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2h-pyrazino[2,1-c][1,2,4]triazine-1(6h)-carboxamide

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110288115A1 (en) 2010-05-24 2011-11-24 Avmedis Llc Treatment of vagally-mediated spectrum disorders
WO2015098853A1 (ja) 2013-12-25 2015-07-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 （６Ｓ，９ａＳ）－Ｎ－ベンジル－６－［（４－ヒドロキシフェニル）メチル］－４，７－ジオキソ－８－（｛６－［３－（ピペラジン－１－イル）アゼチジン－１－イル］ピリジン－２－イル｝メチル）－２－（プロプ－２－エン－１－イル）－オクタヒドロ－１Ｈ－ピラジノ［２，１－ｃ］［１，２，４］トリアジン－１－カルボキサミド化合物
WO2018147275A1 (ja) 2017-02-08 2018-08-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
WO2021086909A1 (en) 2019-10-29 2021-05-06 Eisai R&D Managment Co., Ltd. Combination of a pd-1 antagonist, a vegfr/fgfr/ret tyrosine kinase inhibitor and a cbp/beta-catenin inhibitor for treating cancer

Also Published As

Publication number Publication date
MX2024002060A (es) 2024-03-01
KR20240056487A (ko) 2024-04-30
WO2023038030A1 (ja) 2023-03-16
EP4364742A4 (en) 2025-07-02
JPWO2023038030A1 (https=) 2023-03-16
EP4364742A1 (en) 2024-05-08
CN117794544A (zh) 2024-03-29
TW202327613A (zh) 2023-07-16
AU2022342537A1 (en) 2024-02-15
CA3227813A1 (en) 2023-03-16
US20250222003A1 (en) 2025-07-10

Similar Documents

Publication Publication Date Title
KR102225371B1 (ko) 플리나불린 및 탁산의 조합에 의한 암 치료
KR101673731B1 (ko) 벰루페닙 및 mdm2 억제제의, 증식성 질환 치료용 복합 요법
CN103945849B (zh) 癌症的联合治疗
KR102439911B1 (ko) 제약학적 복합제제
CN103153292B (zh) 联合抗癌疗法的组合物
KR20240112932A (ko) 암 치료를 위한 cdk2 억제제 및 cdk4 억제제를 포함하는 방법 및 투여 섭생법
KR20240112931A (ko) 암 치료를 위한 cdk4 억제제
JP2013521338A (ja) 小細胞肺癌を治療するための方法
US9700565B2 (en) Method of treating mixed lineage leukemia gene-rearranged acute lymphoblastic leukemias
JP2005501825A (ja) エポシロンを含有する組合せ剤およびその医薬上の使用
JP7445826B2 (ja) 固形腫瘍治療用医薬組成物
TW202302084A (zh) 以安森司坦和帕博西尼治療乳癌
TW202227088A (zh) 組合療法
JP7565132B2 (ja) がんの治療又は予防用医薬
TWI922738B (zh) 化合物或其藥劑學上可接受的鹽用於製造實性瘤治療用醫藥組成物之用途
AU2020381240A1 (en) Therapeutic combinations of acalabrutinib and capivasertib to treat B-cell malignancies
TWI814504B (zh) 治療癌症之方法
TWI922768B (zh) 包含cdk4抑制劑之用於治療癌症之方法及給藥方案
US20190160054A1 (en) Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer
CN114761010B (zh) 喹唑啉衍生物或其盐的联用药物组合物及其用途
RU2827402C2 (ru) Фармацевтическая композиция, содержащая пиридинаминное соединение, и ее применение при ros1-положительном немелкоклеточном раке легкого
HK40110657A (zh) 用於治疗癌症的cdk4抑制剂
HK40112852A (zh) 癌的治疗或预防用药物
WO2024255883A1 (zh) Akt抑制剂在制备预防或治疗乳腺癌药物中的用途
HK40069821B (zh) 治疗b细胞恶性肿瘤的阿卡替尼和卡帕塞替尼的治疗组合

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231006

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20231006

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231107

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240226

R150 Certificate of patent or registration of utility model

Ref document number: 7445826

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150